Search companies

Live

MSX (ASX: MSX)

Health care · News and insights

Price unavailable

Latest MSX announcements

Announcement Insights

Miro Sciences Advances Preparations For Crohn’s Trial, Targeting Year-End Start

Miro Sciences has progressed preparations for a planned Phase 2 trial of its StemSmart therapy in treatment-resistant Crohn’s disease, most recently reporting completion of a TGA inspection of its manufacturing partner. After announcing the planned Australian and US trial in October and positive FDA feedback and a clinical research organisation appointment, the company is targeting initiation by the end of 2026, subject to regulatory approvals. It reported approximately $4 million in cash at September-end.

Updated 12 Nov 2026, 09:17 AM Sydney time
Share
SourcesManufacturing Milestone Achieved - TGA Inspection CompletedIntroducing Miro Sciences Ltd - PresentationName Change to Miro Sciences (MSX)
Comments

Miro Sciences Clears TGA Inspection Milestone Ahead Of Planned Crohn’s Trial

2026-11-12 · Health care

MSX: $0.041 +0.00% · MC: $16M

Miro Sciences says the TGA has completed its inspection of manufacturing partner Q-Gen, a step towards supplying StemSmart for a planned Phase 2 trial in treatment-resistant Crohn’s disease, subject to regulatory approvals. The company is targeting trial initiation by the end of 2026, following positive FDA feedback and the appointment of a clinical research organisation in October.

Updated 2026-11-12 09:07
Share
SourcesManufacturing Milestone Achieved - TGA Inspection Completed
Comments

Miro Sciences Pitches Stem Cell Therapy for Severe Crohn’s Disease

2026-11-05 · Health care

MSX: $0.052 +15.56% · MC: $16M

Miro Sciences’ investor presentation positions its StemSmart cell therapy for patients with severe Crohn’s disease who have failed existing treatments, and says the company is preparing for a planned Phase 2 trial in Australia and the United States. The presentation reports approximately $4 million in cash at the end of September and a market capitalisation of approximately $20 million as of November.

Updated 2026-11-05 09:14
Share
SourcesIntroducing Miro Sciences Ltd - Presentation
Comments

NeuroScientific Biopharmaceuticals becomes Miro Sciences as it prepares for planned phase 2 trial

2026-10-28 · Health care

MSX: $0.054 +0.00% · MC: $16M

The company’s name change to Miro Sciences Ltd and ticker change from NSB to MSX took effect after shareholder approval and formal registration. The company says the new identity reflects its focus on its StemSmart cell therapy platform and preparations for a planned phase 2 trial in Australia and the United States for potential treatments for refractory Crohn’s disease.

Updated 2026-10-28 10:27
Share
SourcesName Change to Miro Sciences (MSX)
Comments